ARC Desk

Anticoagulants Market is Heading Up 39 Billion US$ By 2026

Lehdistötiedote   •   Elo 09, 2019 10:27 EEST

According to Acumen Research and Consulting, The global Anticoagulants Market Size is anticipated to around US$ 9 billion by 2026. The market is anticipated to grow at a CAGR of 4% from 2018 to 2026.

Market Overview:

The “Anticoagulants Market– Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026,” report provides analysis of the global Anticoagulants Market for the period from 2016 to 2026, wherein 2018–2026 is the forecast period and 2018 is the base year. Data for 2017 has been included as historical information.

The report covers all trends and technologies expected to play a major role in growth of the global Anticoagulants Market during the forecast period. It highlights drivers, restraints, and opportunities expected to influence the market from 2018 to 2026. The study provides a holistic perspective on the Anticoagulants Market, in terms of revenue (in US$ Mn) and volume (in million units), across different regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South America. The report highlights key trends affecting the Anticoagulants Market at the global level. Prominent countries/sub-regions covered in the report include the U.S., Canada, Germany, France, the U.K., Italy, Russia, India, China, Japan, South Korea, South East Asia, GCC, South Africa, and Brazil.

Download Free Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1201

The report comprises detailed ecosystem analysis, which provides a comprehensive view of the global Anticoagulants Market. Porter’s five forces model has also been included to help understand the competition landscape of the market. Additionally, current indicators of diverse macro-economic factors are contextualized under key market indicators.

The report also analyzes the Anticoagulants Market on the basis of various segments, with drug type being a prominent one. A unique section in the report also offers a detailed breakdown on the basis of route of administration – which one is highly preferred and which one is minimally preferred.

Market Segmentation:

Market By Route of Administration

  • Oral
  • Injectable

Market By Drug Class

  • Factor XA Inhibitors (NOAC/DOAC)
  • Heparins
  • Direct Thrombin Inhibitors
  • Vitamin K Antagonists

Market By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Market By Indication

  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Atrial Fibrillation
  • Heart Attack

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

In terms of consumption of anticoagulants, the North America was the dominant region in the year 2018 and the similar trend is expected to continue over forecast period due to rapid increase in the surgeries such as hip and knee surgeries in this region. Europe region is following the North America in terms of demand for anticoagulants. Increase in geriatric population is expected to be one of the key factor boosting the demand for anticoagulant in this region.

On the other hand, APAC region is expected to register significant CAGR growth rate over forecast period. The increasing health issues due to changing lifestyle as well as increasing surgical operations in this region are some of the prime factors accelerating the demand for anticoagulants in this region. Also, increasing network of healthcare facilities is expected to be another factor creating a demand for anticoagulants.

Market Participants / Key Players:

The key players operating in the global anticoagulants market are Bristol-Myers Squibb Company, Pfizer, Inc., Bayer Healthcare, Sanofi, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., and Daiichi Sankyo Company Limited.

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

What is the overall structure of the market?

What was the historical value and what is the forecasted value of the market?

What are the key product level trends in the market?

What are the market level trends in the market?

Which of the market players are leading and what are their key differential strategies to retain their stronghold?

Which are the most lucrative regions in the market space?

Research Methodology

Secondary research sources that are typically referred to include, but are not limited to company websites, annual reports, financial reports, broker reports, investor presentations, SEC filings, internal and external proprietary databases, relevant patent and regulatory databases, national government documents, statistical databases, market reports, news articles, press releases, webcasts specific to companies operating in the market, national government documents, statistical databases, and Factiva.

Primary research involves e-mail interactions, telephonic interviews, and face-to-face interviews conducted for each market segment across geographies. ARC conducts primary interviews on an ongoing basis with market participants and commentators in order to validate the data and analysis. Primary interviews provide firsthand information on market size, market trends, growth trends, competition landscape, and market outlook. These help validate and strengthen secondary research findings. They also help develop the analysis team’s expertise and market understanding.

VIEW FULL RESEARCH REPORT@ https://www.acumenresearchandconsulting.com/anticoagulants-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Anticoagulants
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Anticoagulants Market By Route of Administration
1.2.2.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.2.2. Global Anticoagulants Market Revenue Share By Route of Administration in 2017
1.2.2.3. Oral
1.2.2.4. Injectable
1.2.3. Anticoagulants Market By Drug Class
1.2.3.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.3.2. Global Anticoagulants Market Revenue Share By Drug Class in 2017
1.2.3.3. Factor XA Inhibitors (NOAC/DOAC)
1.2.3.4. Heparins
1.2.3.5. Direct Thrombin Inhibitors
1.2.3.6. Vitamin K Antagonists
1.2.4. Anticoagulants Market By Distribution Channel
1.2.4.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.4.2. Global Anticoagulants Market Revenue Share By Distribution Channel in 2017
1.2.4.3. Hospital Pharmacies
1.2.4.4. Retail Pharmacies
1.2.4.5. Online Pharmacies
1.2.5. Anticoagulants Market By Indication
1.2.5.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.5.2. Global Anticoagulants Market Revenue Share By Indication in 2017
1.2.5.3. Deep Vein Thrombosis (DVT)
1.2.5.4. Pulmonary Embolism (PE)
1.2.5.5. Atrial Fibrillation
1.2.5.6. Heart Attack
1.2.6. Anticoagulants Market by Geography
1.2.6.1. Global Anticoagulants Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Anticoagulants Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Anticoagulants Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Anticoagulants Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Anticoagulants Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Anticoagulants Major Manufacturers in 2017

CHAPTER 4. ANTICOAGULANTS MARKET BY ROUTE OF ADMINISTRATION

4.1. Global Anticoagulants Revenue By Route of Administration
4.2. Oral
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Injectable
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTICOAGULANTS MARKET BY DRUG CLASS

5.1. Global Anticoagulants Revenue By Drug Class
5.2. Factor XA Inhibitors (NOAC/DOAC)
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Heparins
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Direct Thrombin Inhibitors
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Vitamin K Antagonists
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTICOAGULANTS MARKET BY DISTRIBUTION CHANNEL

6.1. Global Anticoagulants Revenue By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Retail Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Online Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. ANTICOAGULANTS MARKET BY INDICATION

7.1. Global Anticoagulants Revenue By Indication
7.2. Deep Vein Thrombosis (DVT)
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Pulmonary Embolism (PE)
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Atrial Fibrillation
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Heart Attack
7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. NORTH AMERICA ANTICOAGULANTS MARKET BY COUNTRY

8.1. North America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Anticoagulants Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 9. EUROPE ANTICOAGULANTS MARKET BY COUNTRY

9.1. Europe Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 10. ASIA-PACIFIC ANTICOAGULANTS MARKET BY COUNTRY

10.1. Asia-Pacific Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 11. LATIN AMERICA ANTICOAGULANTS MARKET BY COUNTRY

11.1. Latin America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million
11.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million))
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 12. MIDDLE EAST ANTICOAGULANTS MARKET BY COUNTRY

12.1. Middle East Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 13. AFRICA ANTICOAGULANTS MARKET BY COUNTRY

13.1. Africa Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Bristol-Myers Squibb Company
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Pfizer, Inc.
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Bayer Healthcare
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Sanofi
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Boehringer Ingelheim International GmbH
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Johnson & Johnson Services, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Daiichi Sankyo Company Limited
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1201

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.